Pharma Mar, S.A. (LON:0RC6)

Market Cap	1.10B
Revenue (ttm)	147.02M
Net Income (ttm)	16.63M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	66.23
Forward PE	21.82
Dividend	0.55 (0.74%)
Ex-Dividend Date	Jun 25, 2025

Volume	49
Average Volume	718
Open	74.50
Previous Close	73.45
Day's Range	73.85 - 74.55
52-Week Range	29.46 - 107.10
Beta	-0.06
RSI	42.38
Earnings Date	Apr 25, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RC6

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.

Financial numbers in EUR